Target intelligence / Profile preview

Mitochondrial apoptosis

Molecular classification
Other (cellular process), Not a molecule, receptor, enzyme, or transporter
01

Overview

Mitochondrial apoptosis (the intrinsic pathway of apoptosis) is a tightly regulated process of programmed cell death, initiated by intracellular stress signals (such as DNA damage) that trigger a series of molecular events in mitochondria[1][3][5]. Central to this process are members of the Bcl-2 family, which tightly control mitochondrial outer membrane permeabilization (MOMP). Upon activation, pro-apoptotic proteins (Bax, Bak) form pores in the mitochondrial outer membrane, enabling the release of cytochrome c and other pro-apoptotic factors (e.g., SMAC, Apaf-1) into the cytosol. This cascade results in the activation of caspases, ultimately leading to cellular disassembly and efficient clearance by phagocytes. Dysregulation of mitochondrial apoptosis has major implications in diseases such as cancer, neurodegeneration, and ischemic injury[5][2][3]. Therapeutic approaches aim to either induce mitochondrial apoptosis (in cancer) or prevent it (in neurodegeneration, ischemic injury) by targeting specific molecules within the pathway—not the overall process itself[2][4][6].

Other names
Intrinsic apoptosis pathwayMitochondria-mediated apoptosisMitochondrial pathway of apoptosis
02

Mechanism of action

Induction of mitochondrial outer membrane permeabilization (MOMP) via Bcl-2 family modulation Release of cytochrome c and other apoptogenic factors Activation of caspases ROS generation and modulation of mitochondrial metabolism[1][4][5]

03

Biological functions

ApoptosisCell deathHomeostasisSignal transduction (as part of wider apoptotic signaling)
04

Disease associations

Cancer (cancer cells often evade apoptosis via mitochondrial pathway dysregulation)Neurodegenerative disease (excessive apoptosis)Ischemic injury (heart attack, stroke)Autoimmune disease (aberrant apoptosis)Other (developmental defects due to improper apoptosis)
05

Safety considerations

Risk of excessive cell death in healthy tissues (neurodegeneration, tissue atrophy)Potential off-target effects leading to immune dysregulation or impaired tissue repairToxicity due to mitochondrial dysfunction in non-target tissues
06

Interacting drugs

Venetoclax (Bcl-2 inhibitor)

3 more in the full profile.

07

Biomarkers

Expression/activation of Bax, Bak, Bcl-2, Bcl-xL, BH3-only proteinsCytosolic cytochrome c levelsApaf-1 and downstream caspase activationSMAC/DIABLO release

Beyond the preview

Go deeper on Mitochondrial apoptosis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial apoptosis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call